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Abstract 
Autism Spectrum Disorder (ASD) 
is a neurodevelopmental disorder 
of varying severity and phenotypic 
expression that is characterized 
by persistent deficits in social 
relatedness, communication skills, 
and interfering repetitive behaviors. 
Associated behavioral pathology 
can include inattention, aggression, 
irritability, hyperactivity, anxiety, 
and self-injury. Currently, FDA-
approved treatments exist to treat 
secondary symptoms but not core 
symptomatology. The etiology of 
autism and other ASD is thought 
to be multifactorial but is not well 
understood. Some studies suggest 
that glutamate excitotoxicity may 
play a role in the pathogenesis 
of ASD. Memantine, an NMDA-
receptor antagonist, could potentially 
address core symptoms in ASD 
by targeting disease-specific 
pathophysiology. Our patient, an 
11-year-old Caucasian male, began 
treatment with memantine following 
parental request after learning 
of a phase II clinical trial utilizing 
the drug for treatment in autism. 
Following one month of receiving 
memantine 5mg daily the patient 
reportedly began showing increased 
verbal communication at home. 
Despite the patient not exhibiting 
verbal communication on patient 
interview at the clinic, the guardians 
reported that the patient had begun 
using 30 plus newly learned words, 
and had learned to communicate 
via sign language. Continued 
improvement in communication 
was noted over the course of one 
year of treatment with memantine. 
Memantine is not yet approved 
for treatment of ASD. However, 
in this case it appeared effective 
for treating core deficits in verbal 
and non-verbal communication 
in a child with autism. 
Case Report
An 11 year-old Caucasian male 
with Autism Spectrum Disorder 
presented to the outpatient 
psychiatric clinic in October 2012 
to establish care as the family 
wished to obtain a second opinion 
regarding the treatment of their 
child. He was accompanied by his 
biological mother who described 
a long history of severe deficits in 
social interaction, social reciprocity, 
and delayed verbal and non-verbal 
communication skills. He held few 
relationships outside of immediate 
family, never engaged in shared 
play, and showed no interest 
in developing age-appropriate 
friendships. His mother also 
reported that his previous baseline 
symptomatology included episodes 
of agitation and physical aggression, 
sleep disturbance, and hyperkinetic 
motor-behavior. Pharmacotherapy 
included dextroamphetamine 
extended release 10mg PO for 
attention deficit and hyperactivity 
symptoms, clonidine HCL 0.1mg 
for adjunctive treatment of 
ADHD, melatonin 6mg for sleep, 
mirtazapine 7.5mg also for sleep 
and olanzapaine 5mg as needed for 
agitation and irritability. He had trials 
of aripiprazole, then ziprasidone, 
and then guanfacine from November 
2012 to May 2013 prior to starting 
memantine to target his aggressive 
behaviors but they were reported 
to increase these behaviors and 
therefore discontinued. Clonidine 
was started after he failed to have 
a positive response to guanfacine. 
The patient also received in-home 
behavioral therapy once per week, 
speech therapy for thirty minutes 
per week as well as twice-weekly 
occupational therapy. Medication 
changes during the course of this 
case report included discontinuation 
of dextroamphetamine in August 
of 2013 and as needed olanzapine 
in February of 2014 due to 
resolution of symptoms for which 
the medications were prescribed. 
Melatonin was also increased to 
9mg for sleep as of April 2014. 
The patient returned for a regular 
follow-up visit in June 2013. At 
that time his parents reported that 
the child of a family friend was 
involved in a clinical trial assessing 
use of memantine to increase 
social expression for patients 
with ASD and were interested 
in a trial of memantine for this 
purpose. After discussion of risks 
and benefits of the medication as 
well as explanation of off-label 
use the parents expressed their 
understanding and desire to go 
forward with treatment. Memantine 
was started at 2.5mg once daily 
dosing for seven days then 
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increased to 5mg daily where he 
was maintained. 5mg was chosen 
as this dose was the closest 
commercially available equivalent 
to the 3mg or 6mg dosages being 
used in the clinical trial. Follow-
up visits were conducted with the 
patient and his parents roughly 
every 1-3 months following 
memantine initiation and have been 
ongoing for roughly two years. 
Prior to initiation of memantine 
therapy the patient had shown a 
moderate decrease in agitation 
and aggressive symptoms but 
had not shown improvement in 
expressive or receptive linguistic 
capacity. Following the first month 
of therapy the patient’s parents 
reported increased vocal expression 
at home as well as the use of 
new words. Over the course of 
subsequent follow-up visits the 
patient’s verbal expression was 
reported to fluctuate. However, as 
verbal methods of expression would 
wane, new non verbal methods had 
reportedly manifested through the 
use of sign. Four months following 
initiation of memantine therapy the 
patient learned to use rudimentary 
sign language to communicate 
basic wants and needs. By thirteen 
months of treatment the patient’s 
gains in expressive language 
had been maintained and he was 
reported to regularly communicate 
by using both single words and 
signs. His parents estimated that he 
had learned 30 new words in total. 
In addition to improved 
communication skills the patient’s 
parents reported improved sleep, 
mood, and decreased aggression. 
Over roughly a year and a half 
he demonstrated increased 
receptivity to verbal redirection, 
improved fine motor coordination 
with notable gains in handwriting, 
and made gains in mathematics by 
learning to count on both hands. 
Observations were made in both 
the home and the classroom and 
reported by both parents and 
teachers respectively. Of note, 
no new medications were added 
following initiation of memantine. 
Dextroamphetamine was stopped 
in August of 2013 and he no longer 
required as needed olanzapine. 
Discussion
ASD is one of the most common 
pervasive developmental disorders, 
with a roughly 1% prevalence 
worldwide. The diagnosis of 
ASD is based on deficits from 
two primary symptom clusters: 
social-communication deficits and 
restricted or repetitive behaviors. 
Patients often present with multiple 
comorbidities such as sensory 
and motor abnormalities, epilepsy, 
ADHD, mood disorders and 
intellectual disability. Aripiprazole 
and risperidone are the only 
medications with a FDA-approved 
indication specifically related to 
ASD. However, both of these 
agents target “irritability related to 
Autistic Disorder” only. Additionally 
these medications are associated 
with a varying severity of adverse 
Drug or Alcohol Problem? Mental Illness?
If you have a drug or alcohol problem, or are suffering from a mental illness you 
can get help by contacting the West Virginia Medical Professionals Health Program. 
Information about a practitioner’s parti cipation in the program is confidential. Prac ­
titioners entering the program as self­referrals without a complaint filed against them 
are not reported to their licensing board.
304-933-1030
bhallmd@wvmphp.org
www.wvmphp.org
ALL CALLS ARE CONFIDENTIAL
West Virginia Medical Professionals 
Health Program
4013 Buckhannon Pike
Mount Clare, WV 26408
46 W e s t  Vi r g i n i a  M e d i c a l J ou r n a l www.wvsma.org
Case Report  |
drug events such as somnolence, 
weight gain, dyskinesias and 
prolactinemia.1 No pharmacologic 
agent is currently approved to 
treat the core deficits of autism. 
Memantine is a medication within 
the NMDA receptor antagonist 
category and is typically used to 
treat the cognitive deficits associated 
with Alzheimer’s dementia. This 
family of medications acts on 
the NMDA-glutamate pathway to 
down-regulate glutamate induced 
neuronal excitation thought to 
contribute to the neurological 
pathology of dementia-related 
illnesses.2 A similar mechanism 
of glutamate excitotoxicity is 
theorized to be underlay ASD and 
its associated core deficits.3 At the 
time of this writing memantine is 
undergoing phase II clinical trials 
for the purpose of autism therapy. 
Memantine however is not without 
its adverse drug reactions as 
increased irritability, GI disturbance, 
rash, excessive sedation, vomiting 
and possible speech problems are 
all possible with the medication.2 
A review of published reports has 
suggested that memantine can be 
used in therapy to improve core 
areas of deficit, such as eye contact 
and communication. A retrospective 
study conducted by Erickson et 
al elucidated that inattention and 
social interaction may in fact be 
the most significant areas affected 
by the medication, as was seen 
in 61% of the 18 patients studied 
over a course of 19.3 weeks.4 
Memantine also shows promise 
in areas of function peripheral to 
the major core deficits, possibly 
expanding its therapeutic range. An 
open-trial performed by Chez et al 
demonstrated that over a two month 
period of therapy 26 of 30 (87%) 
patients showed improvement in 
one or more categories of attention, 
motor planning, language function 
and self-stimulatory behaviors.5 
Memantine has also been reviewed 
as an adjunctive to currently used 
therapies such as risperidone. In 
another open-label study performed 
by Chez et al, it was demonstrated 
that of the patient population 
studied 82.7% showed a positive 
response in language improvement 
with receptive language showing 
the most improvement alongside 
improvements in length of 
sentence and speech fluency.2 
Not all trials and case reports 
have shown positive effect however. 
One study by Owley et al found no 
increase in baseline of expressive 
or receptive language despite an 
8-week trial of memantine. The 
authors did however describe 
improvement in memory-related 
testing and suggested that language 
improvement may have occurred 
with a longer medication trial.6 
A more recent study by Aman et 
al demonstrated some moderate 
improvement in communication, 
sustained over the course of a 
48-week study arm, however the 
changes were ultimately found to 
be statistically non-significant.7 An 
additional case report performed 
by Alaghband-Rad et al suggested 
a possible adverse drug related 
event of stuttering and difficulty with 
speech initiation that appeared to 
begin and resolve with memantine 
initiation and cessation respectively. 
However the case report only 
included two individuals, one of 
which did have prior history of 
stuttering beginning at the age of 
four. Additionally, the case report 
mentions that the episodes of 
speech impediment decreased over 
time but only returned to baseline 
with the withdrawal of mementine.8 
Our case report contributes 
to the relatively sparse literature 
describing NMDA antagonist 
therapy for treatment of core ASD 
symptomatology. Similar to previous 
reports our patient was observed 
to demonstrate improvement 
in multiple areas of function. 
Observations from both parents and 
the patient’s school consistently 
reported improvement in sociality, 
communication and aggressive 
behavior with the most notable 
gains occurring in the use of both 
verbal and non-verbal expressive 
language. Despite reported overall 
symptomatic improvement, it must 
be noted that the patient did not 
demonstrate increased verbal or 
non-verbal communication skills 
during clinical appointments, 
however it is felt that this was likely 
due to discomfort with interaction 
in a non-routine and relatively 
unfamiliar environment. With a single 
case it is impossible to definitively 
show causality but the timing of 
medication administration and 
subsequent symptom improvement 
is suggestive. Spontaneous rapid 
improvement in language skills 
outside of a developmentally 
sensitive period seems unlikely. We 
cannot entirely exclude uncontrolled 
environmental influences such as 
increased attention to language 
instruction by parents and teachers 
once the medication was started. 
Further, it is unclear how much 
associated symptom improvement 
was due to medication effect and 
how much may have been attributed 
to improved communication alone. 
For example, as the patient’s 
ability to express his wants and 
needs increased perhaps his 
frustration, mood, openness to 
redirection and instruction, and 
overall daily functioning may have 
improved as a consequence. 
Conclusion
The core symptoms of ASD are 
highly impairing and negatively 
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impact function across settings. 
There are currently no medications 
with FDA indications that target core 
illness symptomatology. Published 
reports describing improved social 
and communication skills with 
use of memantine are promising 
and deserve further study. 
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